https://mindmedicinelaw.com/briefing/nmda-receptors-and-lhb-burst-firing-new-insights-20260611-12241The Psychedelic Journalen2026-06-12T15:06:43.198881+00:00NMDA Receptors and LHb Burst Firing: New InsightsNMDA receptors, lateral habenula, burst firing, depression treatment, ketamine, neuroscience research, antidepressants, NMDAR antagonists, neural mechanisms, clinical implicationshttps://mindmedicinelaw.com/briefing/neurobiology-of-depression-anxiety-implications-for-psychedelic-research-20260611-12242The Psychedelic Journalen2026-06-12T15:06:33.136539+00:00Neurobiology of Depression & Anxiety: Implications for Psychedelic Researchneurobiology of depression, anxiety disorders, psychedelic therapies, neurotransmitter systems, neural circuitry, precision psychiatry, neuroinflammation, genetic influences, HPA axis dysfunctionhttps://mindmedicinelaw.com/briefing/biopsychosocial-framework-for-addiction-implications-for-psychedelic-therapies-20260611-12192The Psychedelic Journalen2026-06-12T15:06:23.533065+00:00Biopsychosocial Framework for Addiction: Implications for Psychedelic Therapiesbiopsychosocial framework, addiction models, psychedelic-assisted therapy, neuroscience, public health, clinical trials, psychosocial factors, addiction treatment, multidimensional approach, emerging interventionshttps://mindmedicinelaw.com/briefing/telehealth-ketamine-for-depression-review-insights-20260611-12297The Psychedelic Journalen2026-06-12T15:05:52.199248+00:00Telehealth Ketamine for Depression: Review Insightstelehealth ketamine, depression treatment, anxiety treatment, psychedelic-assisted therapy, mental health care, systematic review, telemedicine, NMDA receptor antagonisthttps://mindmedicinelaw.com/briefing/colorado-s-ibogaine-law-and-its-impact-on-psilocybin-regulation-20260611-11993The Psychedelic Journalen2026-06-11T15:03:54.910697+00:00Colorado's Ibogaine Law and Its Impact on Psilocybin Regulationcolorado ibogaine law, psilocybin regulation, psychedelic substances, unlicensed sales, market dynamics, legal compliancehttps://mindmedicinelaw.com/briefing/survey-reveals-variability-in-ketamine-assisted-psychotherapy-20260610-12229The Psychedelic Journalen2026-06-12T15:06:03.746754+00:00Survey Reveals Variability in Ketamine-Assisted Psychotherapyketamine-assisted psychotherapy, depression treatment, psychedelic therapy, clinical trials, psychotherapy modalities, neuroplasticity, evidence-based standardshttps://mindmedicinelaw.com/briefing/breathwork-s-potential-in-inducing-altered-states-of-consciousness-20260610-12037The Psychedelic Journalen2026-06-11T22:05:34.522123+00:00Breathwork's Potential in Inducing Altered States of Consciousnessbreathwork, altered states of consciousness, psychedelics, therapeutic applications, non-pharmacological interventions, mental health, clinical trials, emotional breakthroughs, consciousness research, psychological insightshttps://mindmedicinelaw.com/briefing/molecular-features-in-lewy-body-dementia-cortical-atrophy-20260610-12070The Psychedelic Journalen2026-06-11T22:05:22.585307+00:00Molecular Features in Lewy Body Dementia Cortical Atrophylewy body dementia, cortical atrophy, molecular pathways, neurodegenerative research, clinical trials, GABAergic signaling, mitochondrial function, synaptic transmission, Parkinson's disease, Alzheimer's diseasehttps://mindmedicinelaw.com/briefing/machine-learning-enhances-autism-mouse-model-profiling-20260610-12071The Psychedelic Journalen2026-06-11T22:05:13.731133+00:00Machine Learning Enhances Autism Mouse Model Profilingmachine learning, autism spectrum disorder, behavioral profiling, genetic mouse models, psychedelic research, neurodevelopmental disorders, Shank3B knockout mice, phenotype detection, translational studies, therapeutic interventionshttps://mindmedicinelaw.com/briefing/patient-views-on-psychedelic-therapy-for-aud-insights-and-implications-20260610-12035The Psychedelic Journalen2026-06-11T22:04:58.061715+00:00Patient Views on Psychedelic Therapy for AUD: Insights and Implicationsalcohol use disorder, psychedelic therapy, patient perceptions, clinical trials, informed consent, treatment expectations, addiction treatment, ethical researchhttps://mindmedicinelaw.com/briefing/ethical-challenges-in-ketamine-therapy-in-norway-20260610-12082The Psychedelic Journalen2026-06-11T22:04:44.912073+00:00Ethical Challenges in Ketamine Therapy in Norwayketamine-assisted psychotherapy, ethical challenges, Norway, treatment-resistant depression, informed consent, therapeutic integrity, access to care, psychedelic therapies, principlist bioethics, health policyhttps://mindmedicinelaw.com/briefing/optimi-health-ships-psilocybin-to-uk-for-clinical-trials-20260610-11992The Psychedelic Journalen2026-06-11T15:04:04.628301+00:00Optimi Health Ships Psilocybin to UK for Clinical Trialsoptimi health, psilocybin shipment, clinical trials, international collaboration, psychedelic research, UK regulatory framework, therapeutic potential, cross-border supply, controlled substances, regulatory approvalshttps://mindmedicinelaw.com/briefing/epa-s-tsca-chemical-review-implications-for-psychedelics-20260610-11546The Psychedelic Journalen2026-06-10T22:04:18.636255+00:00EPA's TSCA Chemical Review: Implications for PsychedelicsEPA, TSCA, chemical review, psychedelic substances, regulatory compliance, market strategy, premanufacture notice, significant new use, microbial commercial activity, legal implicationshttps://mindmedicinelaw.com/briefing/nevada-expands-ketamine-program-in-mental-health-care-20260610-11838The Psychedelic Journalen2026-06-10T22:04:10.009051+00:00Nevada Expands Ketamine Program in Mental Health Careketamine program, interventional psychiatry, psychedelic-assisted therapy, mental health treatment, Nevada healthcare, clinical trials, psychedelic research, policy implications, patient access, treatment innovationhttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-export-to-uk-a-clinical-milestone-20260610-11837The Psychedelic Journalen2026-06-10T22:03:59.487627+00:00Optimi Health's Psilocybin Export to UK: A Clinical Milestonepsilocybin export, Optimi Health, UK Phase 2 trial, psychedelic research, international collaboration, regulatory frameworks, mental health treatments, clinical trials, therapeutic applications, market dynamicshttps://mindmedicinelaw.com/briefing/gpcr-biased-signaling-new-frontiers-in-psychedelic-therapies-20260609-11609The Psychedelic Journalen2026-06-10T22:04:28.262478+00:00GPCR Biased Signaling: New Frontiers in Psychedelic TherapiesGPCR biased signaling, psychedelic therapies, drug development, clinical trials, serotonin receptor, mental health, pharmacology, regulatory frameworks, therapeutic innovation, signaling pathwayshttps://mindmedicinelaw.com/briefing/psychedelics-structure-activity-therapeutic-implications-20260608-12137The Psychedelic Journalen2026-06-11T22:05:05.400544+00:00Psychedelics: Structure-Activity & Therapeutic Implicationspsychedelic pharmacology, structure-activity relationships, neuropsychiatric disorders, clinical trial design, mental health treatment, psychedelic therapyhttps://mindmedicinelaw.com/briefing/psychedelics-in-hospital-psychiatry-future-directions-20260604-11643The Psychedelic Journalen2026-06-10T22:04:38.079521+00:00Psychedelics in Hospital Psychiatry: Future Directionspsychedelic treatments, hospital psychiatry, clinical trials, neuroplasticity, policy considerations, psychiatric care, psilocybin, MDMA, patient safety, therapeutic outcomeshttps://mindmedicinelaw.com/briefing/psychedelics-in-palliative-care-new-evaluation-published-20260602-12301The Psychedelic Journalen2026-06-12T15:06:13.851356+00:00Psychedelics in Palliative Care: New Evaluation Publishedpsychedelics, palliative care, end-of-life care, psilocybin, MDMA, clinical trials, patient well-being, policy implications, therapeutic use, psychoactive substanceshttps://mindmedicinelaw.com/briefing/ipa-s-depression-dementia-research-roadmap-future-directions-20260601-11582The Psychedelic Journalen2026-06-10T22:04:46.959250+00:00IPA's Depression-Dementia Research Roadmap: Future Directionsdepression, dementia, neurocognitive disorders, psychedelic therapies, biomarkers, precision psychiatry, caregiver burden, diagnostic criteria, multimodal interventions, brain healthhttps://mindmedicinelaw.com/briefing/psychedelics-influence-on-personality-updated-insights-20260531-11656The Psychedelic Journalen2026-06-11T15:04:13.161108+00:00Psychedelics' Influence on Personality: Updated Insightspsychedelics, personality traits, systematic review, therapeutic applications, individual variability, serotonin receptors, clinical trials